Dermatology

Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022

Retrieved on: 
Wednesday, October 5, 2022

Product revenues for the third quarter of 2022 are anticipated to be approximately $4.3 million, consistent with the third quarter of 2021.

Key Points: 
  • Product revenues for the third quarter of 2022 are anticipated to be approximately $4.3 million, consistent with the third quarter of 2021.
  • Year-to-date 2022 product revenues are at a record high, and are up approximately 26% over the comparable period in the pre-Covid year 2019.
  • The preliminary unaudited product revenues described in this press release are estimates only and are based on currently available information.
  • Biofrontera expects to report financial results for the third quarter of 2022 in the first half of November 2022.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, October 5, 2022

These awards were approved by the Compensation Committee of Arcutis Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 1, 2022, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These awards were approved by the Compensation Committee of Arcutis Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 1, 2022, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options have a ten-year term and an exercise price of $19.20 per share, equal to the per share closing price of Arcutis common stock as reported by Nasdaq on October 3, 2022.
  • Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions.
  • We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Removery Turns 100th Studio Opening Into Fundraising For Florida

Retrieved on: 
Tuesday, October 4, 2022

FT. LAUDERDALE, Fla., Oct. 4, 2022 /PRNewswire/ -- Removery is turning the celebration of its 100th location opening on Oct. 4 into a day of fundraising for Florida residents and communities affected by Hurricane Ian.

Key Points: 
  • Laser tattoo removal company to support affected residents, and communities
    FT. LAUDERDALE, Fla., Oct. 4, 2022 /PRNewswire/ -- Removery is turning the celebration of its 100th location opening on Oct. 4 into a day of fundraising for Florida residents and communities affected by Hurricane Ian.
  • Funds will aid Hurricane Ian relief efforts in honor of the 100th studio's location at 721 N. Federal Highway in Ft. Lauderdale, FL.
  • "As our team members and clients from studios across Florida sought shelter, we knew we wanted to help them feel supported and safe," said Tom Weber, CEO of Removery.
  • "So it's fitting that South Florida is the home of our 100th location, because Removery exists to help people feel their best, express their authentic selves, and normalize tattoo removal."

Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences

Retrieved on: 
Tuesday, October 4, 2022

SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Journey Medical) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will participate in two upcoming investor conferences.

Key Points: 
  • SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Journey Medical) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will participate in two upcoming investor conferences.
  • Journey Medical Corporation (Nasdaq: DERM) (Journey Medical) is focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model.
  • The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatologys most successful prescription brands.
  • As used below and throughout this press release, the words we, us and our may refer to Journey Medical.

TrialSpark announces partnership with major pharmaceutical company to jointly acquire and develop clinical-stage novel therapies

Retrieved on: 
Tuesday, October 4, 2022

NEW YORK, Oct. 4, 2022  /PRNewswire/ -- TrialSpark today announced a new partnership with global pharmaceutical company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently. The collaboration will focus on jointly pursuing the acquisition/in-licensing and development of best-in-class, clinical-stage Phase II and Phase III drug candidates in areas of high unmet patient need.

Key Points: 
  • "We are excited to initiate this novel collaboration with TrialSpark, as another example of our commitment to innovation in the healthcare ecosystem" said, Alban de La Sablire, Partnering Head, Sanofi.
  • "It is a privilege to partner with Sanofi to jointly acquire and develop new treatments," said Benjamine Liu, TrialSpark's CEO and Co-Founder.
  • The Sanofi and TrialSpark partnership formally launched in September 2022, jointly targeting six transactions over the course of the next three years.
  • Founded in 2016, TrialSpark is a tech-driven pharma company differentiated by radically more efficient drug development.

LR Health & Beauty Enters a New Beauty Era

Retrieved on: 
Tuesday, October 4, 2022

With the launch of its new product, LR Health & Beauty once again proves its innovative strength.

Key Points: 
  • With the launch of its new product, LR Health & Beauty once again proves its innovative strength.
  • View the full release here: https://www.businesswire.com/news/home/20221004005596/en/
    With the launch of the new ZEITGARD PRO COSMETIC DEVICE, LR Health & Beauty once again proves its innovative strength.
  • We are proud to introduce the new ZEITGARD PRO, a real high-tech product that significantly improves the daily beauty routines of our customers.
  • Following the motto More quality for your life, the LR Group with headquarters in Ahlen/Westphalia produces and markets various health and beauty products in 28 countries.

DermTech Presents on Technological Advances and the Value of Decentralization at Outsourcing in Clinical Trials Southern California

Retrieved on: 
Monday, October 3, 2022

The presentation, titled Technological Advances in Clinical Trials Exploring the Value of Decentralization, emphasized how the traditional approach to clinical trials can be inconvenient and inaccessible for patients, leading to lesser quality data.

Key Points: 
  • The presentation, titled Technological Advances in Clinical Trials Exploring the Value of Decentralization, emphasized how the traditional approach to clinical trials can be inconvenient and inaccessible for patients, leading to lesser quality data.
  • Finally, she expanded on the role of DermTech Stratum , DermTechs translational medicine service offering, in clinical trials.
  • We are honored to have been a part of Outsourcing in Clinical Trials Southern California to share our perspective on the new wave of decentralization in clinical trials and how this will ultimately improve the patient experience, said Lanni.
  • She has spent more than 10 years managing industry-sponsored clinical trials in biotech, contract research organization (CRO) and academic settings.

Tarrant Dermatology Consultants Joins Epiphany Dermatology

Retrieved on: 
Monday, October 3, 2022

Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in Texas through its partnership with D. Scott Miller, MD, Boris Ioffe, DO, and their team at Tarrant Dermatology Consultants, based in Fort Worth, Texas.

Key Points: 
  • Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in Texas through its partnership with D. Scott Miller, MD, Boris Ioffe, DO, and their team at Tarrant Dermatology Consultants, based in Fort Worth, Texas.
  • Tarrant Dermatology Consultants was founded in 1948 as one of the first dermatology practices in the Dallas-Fort Worth Metroplex.
  • Tarrant Dermatology Consultants has a solid reputation of providing high-quality dermatology services to patients from its two clinic locations in Fort Worth and Weatherford .
  • Epiphany also benefits from the clinical expertise of Tarrant Dermatologys team, as best practices are collaboratively shared across the Epiphany network.

Alcanza Brings Equity to R&D with the First-of-a-Kind Site Network Focused on Inclusive Clinical Research

Retrieved on: 
Monday, October 3, 2022

Founded in December 2021 and named for the Spanish word "reach," Alcanza is a clinical research site network platform dedicated to creating a sustainable and inclusive clinical trial environment for all.

Key Points: 
  • Founded in December 2021 and named for the Spanish word "reach," Alcanza is a clinical research site network platform dedicated to creating a sustainable and inclusive clinical trial environment for all.
  • These include Coastal Carolina Research Center, Boston Clinical Trials, ActivMed and Allcutis Research, Quest Research Institute and Charlottesville Medical Research across eight locations in Massachusetts, Michigan, New Hampshire, South Carolina and Virginia.
  • Alcanza Clinical Research is the next-generation site network established to support the most significant demands in our industry: diverse patient access, efficient enrollment performance and clinical quality.
  • It practices inclusive clinical research that delivers education and a range of clinical trial opportunities to all people on their terms.

Independence Blue Cross offers affordable 2023 Medicare Advantage plans that feature broad access to care and enhanced benefits

Retrieved on: 
Monday, October 3, 2022

PHILADELPHIA, Oct. 3, 2022 /PRNewswire/ -- Independence Blue Cross (Independence) today announced its 2023 Medicare Advantage offerings.

Key Points: 
  • PHILADELPHIA, Oct. 3, 2022 /PRNewswire/ -- Independence Blue Cross (Independence) today announced its 2023 Medicare Advantage offerings.
  • Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
  • Independence Blue Cross offers Medicare Advantage plans with a Medicare contract.
  • Independence Blue Cross offers products through its subsidiaries Independence Hospital Indemnity Plan, Keystone Health Plan East and QCC Insurance Company independent licensees of the Blue Cross and Blue Shield Association.